Page 2898 - Cote clinical veterinary advisor dogs and cats 4th

Boldface page numbers indicate chapter titles. Page numbers followed by a indicate algorithms; b, boxes; e, electronic content; f, figures; and t, tables. 1545

Midol. See Acetaminophen Miniature schnauzer (Continued) Monoclonal gammopathy
Migrating foreign body, 355 megaesophagus in, 642 associated conditions, 1253
melanoma in, 644
multiple myeloma/plasma cell tumor and, 665
Mik erythrocyte antigen, 1316
VetBooks.ir Milbemycin oxime, 567 mycobacterial disease in, 670 Monocytes, 1366
protein electrophoresis, 1376
myotonia congenita in, 676.e2
adverse effects of, 1510.e6t
for Baylisascaris infection, 114.e2
nephrolithiasis in, 689
Monocytic ehrlichiosis, 285–288
for cheyletiellosis, 155
for demodicosis, 246 obsessive-compulsive disorder in, 702 Monocytopenia, 1366
Monocytosis, 1366
oronasal fistula in, 720
drug interactions, 1510.e1t–1510.e5t pancreatitis in, 742 Monocytotropic ehrlichiosis, 285
for heartworm disease, 420 papillomas in, 752 Monteban. See Narasin
for lung parasites, 596 persistent Müllerian duct syndrome in, 780.e3 Monteggia fracture, 291, 367
for nasal mites, 680.e2, 887 pigmentary abnormalities in, 195 Morning-noon-and-night, 138.e6
for otodectic mange, 731 pulmonic stenosis in, 844 Morphine
sensitivity to, MDR1 mutation and, 639 pustular and crusting skin disorders in, 848 for acute heart failure, 409
toxicosis from, 567 rectoanal congenital anomalies/atresia ani in, 867.e2 administration and dosage of, 1490
for whipworm infection, 1049 recurrent flank alopecia in, 869 for necrotizing fasciitis, 685
Miliary dermatitis regurgitation in, 873 for pancreatitis, 741
atopic dermatitis and, 92 retinal detachment in, 885 Mosquito bite hypersensitivity, and pinnal disease, 790
cheyletiellosis and, 155 sick sinus syndrome in, 916 Mosquito-borne diseases
feline alopecia and, 45 squamous cell carcinoma in, 939 heartworm disease, 418–420
otodectic mange and, 731 stunted growth in, 946 tularemia, 999–1000
pediculosis and, 768 urolithiasis in, 1014, 1014.e2, 1016, 1019 Mothball toxicosis, 661.e2–661.e3
Milk let–down, delayed, 570 vitamin A–responsive dermatosis in, 214 Motor nerve conduction velocity (NCV), 1097.e1–
Milk of Magnesia. See Magnesium hydroxide von Willebrand disease in, 1043 1097.e3, 1097.e1f–1097.e3f
Milk replacement formulas, 147, 688 Miniature wirehaired dachshund, myoclonic epilepsy Motor vehicle accident, 477
Milk thistle. See Silymarin (silybin) in, 661 Motrin. See Ibuprofen
Miltefosine Minimally invasive plate osteosynthesis techniques, 361 Mounting, 115
administration and dosage of, 1490 Minipress. See Prazosin Mouth. See Oral cavity
for leishmaniasis, 580 Minocin. See Minocycline Mouth odor, 402–403
Miltex. See Miltefosine Minocycline, 1490 Movement disorders
Mineralocorticoids for cyclic thrombocytopenia, 232.e3 characteristics of, 661–663
deficiency of, 512–515, 514.e1f for granulocytic anaplasmosis, 394 seizures vs., 903
supplementation of, for hypoadrenocorticism, 514 Mintezol. See Thiabendazole Moxidectin, 567
Miniature bull terrier, 657. See also Bull terrier Minute virus of canines, and abortion, 2 adverse effects of, 1510.e6t
Miniature dachshund. See also Dachshund Miosis, 846 for demodicosis, 246
neck ventroflexion in, 684.e2 MiraVista fungal testing, 1365–1366 drug interactions, 1510.e1t–1510.e5t
pneumocystosis in, 793.e2 Mirtazapine for otodectic mange, 731
Miniature pinscher administration and dosage of, 1490 sensitivity to, MDR1 mutation and, 639
aseptic necrosis of femoral head in, 80 as appetite stimulant, 746 toxicosis from, 567
pannus in, 748 Mismating. See Pregnancy, termination of Moxidectin-imidacloprid
pattern alopecia in, 766 Misoprostol for cheyletiellosis, 155
pulmonic stenosis in, 844 administration and dosage of, 1490 for demodicosis, 246
von Willebrand disease in, 1043 for aspirin toxicosis, 83.e3 for heartworm disease, 417
Miniature poodle. See also Poodle for gastric ulcer, 382 for sarcoptic mange, 900–901
alopecia X in, 44 for panosteitis, 750 Mozobil. See Plerixafor
aseptic necrosis of femoral head in, 80 Mitaban toxicosis. See Amitraz 4-MP (4-methylpyrazole). See Fomepizole
atrial rupture in, 98 Mite infestation. See Acariasis MRI. See Magnetic resonance imaging (MRI)
bronchiectasis in, 132 Mitomycin C, 311 MRSA. See Methicillin-resistant staphylococcal
cataracts in, 147 Mitotane (o,p’DDD) infections
cerebellar cortical degeneration in, 149.e3 for aberrant adrenocortical disease, 513 Mu receptors, 711
Chiari-like malformation in, 156 administration and dosage of, 1490 Mucin tear deficiency, 961.e2
collapsing trachea in, 194 for adrenal mass, incidental, 513 Mucocele
diabetes mellitus in, 253.e2 for adrenal neoplasia, 36 gallbladder, 374–375
ectopic ureter in, 282 for alopecia X, 45 salivary
Eisenmenger’s syndrome in, 288.e2 for hyperadrenocorticism, 487, 1425.e1a, 1426a, orbital disease and, 716–718
entropion in, 296 1426.e1a–1426.e2a treatment algorithm for, 1437.e1a
glaucoma in, 387 Mitoxantrone Mucocutaneous pyoderma, 851
myoclonic epilepsy in, 661 administration and dosage of, 1490 cutaneous lupus erythematosus vs., 228–229
nephrolithiasis in, 689 for mesothelioma, 651 Mucolipidosis II, 945.e2–945.e3
oronasal fistula in, 720 for transitional cell carcinoma, 992 Mucolytics
patellar luxation in, 763 Mitral regurgitation, myxomatous valve disease and, for bacterial rhinitis, 890.e3
patent ductus arteriosus in, 764 658–661 for lymphoplasmacytic rhinitis, 891
persistent deciduous teeth in, 238 Mitral valve Mucopolysaccharidosis type I, 945.e2–945.e3
pupil abnormalities in, 846 disease of, 658 Mucopolysaccharidosis type II, 945.e2–945.e3
pyruvate kinase deficiency in, 59 dysplasia of, 657–658 Mucopolysaccharidosis type VI, 945.e2–945.e3
rectoanal congenital anomalies/atresia ani in, 867.e2 replacement of, 658 Mucosal associated lymphoid tissue lymphoma. See
salivary gland disorders in, 894 systolic anterior motion of, 505–507, 948 Gastrointestinal lymphoma
squamous cell carcinoma in, 939 Mixed acid-base disorders, 15.e2–15.e3 Mucous membranes
sterile nodular panniculitis in, 747 Mobic. See Meloxicam oral ulcers, 1002–1003
stunted growth in, 946 Mobitz type I/type II heart block. See Atrioventricular pallor, 736–737
urinary incontinence in, 538 block ulcerative/erosive lesions of, 1452a
urolithiasis in, 1014, 1014.e2, 1016 Modeling clay, salt toxicosis and, 900.e2 Müllerian duct syndrome, persistent, 780.e3
Miniature schnauzer Modified Glasgow Coma Score, 406, 406t Müllerian inhibiting substance type II receptor, 780.e3
ataxia in, 86 Modified live vaccine, 454.e3 Multicentric lymphoma. See Lymphoma, multicentric
cataracts in, 147 Modified transudates, 2.e3 Multidrug resistance (MDR1) mutation, 638–640
cerebellar cortical degeneration in, 149.e3 MODS. See Multiple organ dysfunction syndrome (MODS) Multidrug resistant Escherichia coli, 234
diabetes mellitus in, 251, 253.e2 Moeller-Barlow disease. See Hypertrophic osteodystrophy Multilobular osteochondrosarcoma, 714
fibrocartilaginous embolism in, 336 (HOD) Multilobular tumor of bone, 714
gallbladder mucocele in, 374 Moist eczema, 26 Multimodal analgesia, 735
hyperlipidemia in, 497 Mole bean. See Castor bean toxicosis Multimodal environmental modification, 333
hypernatremia in, 498 Mole killer, 1051 Multipartite sesamoids, 783.e1
hyphema in, 511 Molecular markers, 621 Multiple endocrine neoplasia syndrome, 629.e2
hypothyroidism in, 525 Monensin, 563.e2 Multiple myeloma, 663–665, 893
immune-mediated hemolytic anemia in, 60 Monoamine oxidase inhibitors, 111, 736. See also hyperviscosity syndrome and, 510
keratoconjunctivitis sicca in, 569 Amitraz; Selegiline spinal, 932
www.ExpertConsult.com